Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10181023 | 0.82 | CYP1A2 (0.53) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL5092353 | 0.80 | CYP1A2 (0.57) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL3405403 | 0.80 | KDM4E (0.55) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL669091 | 0.78 | ALDH1A1 (0.64) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL577637 | 0.78 | POLB (0.53) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL8404026 | 0.78 | ALDH1A1 (0.64) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL12883191 | 0.75 | CYP1A2 (0.47) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL30501799 | 0.75 | ALDH1A1 (0.50) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL21884142 | 0.74 | CYP1A2 (0.50) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL2703472 | 0.74 | CYP1A2 (0.70) | CYP1A2ALDH1A1KDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-7875631-B2 | e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed | ANALYTECON S.A. (CH) | 2011-01-25 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| EP-1439169-B1 | DIFLUOROALKENE DERIVATIVE, PEST CONTROL AGENT CONTAINING THE SAME, AND INTERMEDIATE THEREFOR | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1732898-B1 | TETRAHYDROISOQUINOLINE- AND TETRAHYDROBENZAZEPINE DERIVATIVES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7273878-B2 | Difluoroalkene derivative, pest control agent containing the same, and intermediate therefor | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-20040248872-A1 | Difluoroalkene derivative, pest control agent containing the same, and intermediate therefor | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1439169-A1 | DIFLUOROALKENE DERIVATIVE, PEST CONTROL AGENT CONTAINING THE SAME, AND INTERMEDIATE THEREFOR | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CYP1A2 2850/4885ALDH1A1 1930/4885KDM4E 4164/4885 |
| US-20040248872-A1 | Difluoroalkene derivative, pest control agent containing the same, and intermediate therefor | DDT, WEE1, NOTUM | CYP1A2 738/4885ALDH1A1 875/4885KDM4E 1056/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CYP1A2 2850/4885ALDH1A1 1930/4885KDM4E 4164/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CYP1A2 2850/4885ALDH1A1 1930/4885KDM4E 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.